Inovio (INO) Pharmaceuticals announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares of common stock in the proposed offering will be sold by Inovio. Piper Sandler & Co. is acting as sole book-running manager for the offering.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INO:
- Inovio reports Q3 EPS (87c), consensus (48c)
- Options Volatility and Implied Earnings Moves Today, November 10, 2025
- Options Volatility and Implied Earnings Moves This Week, November 10 – November 14, 2025
- Is INO a Buy, Before Earnings?
- Inovio Pharmaceuticals: Hold Rating Amid Promising Developments and Significant Risks